A detailed history of Comerica Bank transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Comerica Bank holds 1,089 shares of DNLI stock, worth $26,375. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,089
Previous 415 162.41%
Holding current value
$26,375
Previous $9,000 244.44%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$20.96 - $31.05 $14,127 - $20,927
674 Added 162.41%
1,089 $31,000
Q2 2024

Aug 15, 2024

BUY
$14.96 - $23.22 $89 - $139
6 Added 1.47%
415 $9,000
Q1 2024

May 15, 2024

SELL
$15.83 - $23.35 $3,197 - $4,716
-202 Reduced 33.06%
409 $8,000
Q4 2023

Feb 14, 2024

BUY
$16.2 - $23.18 $4,746 - $6,791
293 Added 92.14%
611 $13,000
Q3 2023

Nov 21, 2023

BUY
$20.63 - $30.17 $6,560 - $9,594
318 New
318 $6,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.25B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Comerica Bank Portfolio

Follow Comerica Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.